Form 4: Boundless Bio Chief Medical Officer Acquires 180,000 Stock Options

Robert Doebele, Chief Medical Officer of Boundless Bio, acquired 180,000 stock options on February 3, 2025, according to a recent SEC filing.

Summary

• Robert Doebele, the Chief Medical Officer of Boundless Bio, acquired 180,000 stock options on February 3, 2025.
• The options have an exercise price of $2.23 per share.
• The options vest over four years, with 25% vesting on February 3, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• Vesting is contingent upon continued employment with Boundless Bio.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management and shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the options is dependent on the future performance of Boundless Bio's stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the executive.

Future Outlook

The vesting schedule of the options is tied to continued employment, suggesting a long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry, similar to companies like Amgen, Gilead, and Regeneron.
• The four-year vesting schedule with a one-year cliff is also a common practice, aligning with industry norms for incentivizing long-term performance.
• The exercise price of $2.23 is specific to Boundless Bio's valuation and is not directly comparable to other companies without further context.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning executive interests with company performance.
• The vesting schedule encourages long-term commitment from the Chief Medical Officer, which could benefit the company's strategic goals.

Key Dates

Keywords

stock options, executive compensation, insider trading, SEC Form 4, Boundless Bio, Robert Doebele, vesting